Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $2.3 billion.

  • Novartis Ag's Cash from Operations fell 4600.52% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.1 billion, marking a year-over-year increase of 865.54%. This contributed to the annual value of $19.1 billion for FY2025, which is 865.54% up from last year.
  • Latest data reveals that Novartis Ag reported Cash from Operations of $2.3 billion as of Q4 2025, which was down 4600.52% from $6.6 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Cash from Operations high stood at $6.7 billion for Q2 2025, and its period low was $1.6 billion during Q1 2022.
  • For the 5-year period, Novartis Ag's Cash from Operations averaged around $4.0 billion, with its median value being $4.0 billion (2021).
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 7295.33% in 2023, then plummeted by 4600.52% in 2025.
  • Over the past 5 years, Novartis Ag's Cash from Operations (Quarter) stood at $3.9 billion in 2021, then grew by 5.84% to $4.1 billion in 2022, then crashed by 38.04% to $2.5 billion in 2023, then skyrocketed by 64.63% to $4.2 billion in 2024, then tumbled by 46.01% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q4 2025, $6.6 billion for Q3 2025, and $6.7 billion during Q2 2025.